Technical Analysis for GLSI - Greenwich LifeSciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 13.98 | -3.25% | -0.47 |
Earnings due: May 22
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Weak + Overbought | Other | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -3.25% | |
| NR7 | Range Contraction | -3.25% | |
| Narrow Range Bar | Range Contraction | -3.25% | |
| Stochastic Reached Overbought | Strength | -3.25% | |
| Weak + Overbought | Other | -3.25% | |
| Weak, Overbought and Reversal Signs | Reversal | -3.25% | |
| Overbought Stochastic | Strength | -3.25% | |
| Crossed Above 20 DMA | Bullish | 2.49% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | 2 days ago |
| Down 3% | 2 days ago |
| Down 2 % | 2 days ago |
| Fell Below 10 DMA | 2 days ago |
| Non-ADX 1,2,3,4 Bearish Retracement Entry | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 05/22/2024
Greenwich LifeSciences, Inc. Description
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein. In a randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (p = 0.0338). Of the 138 patients that have been treated with GP2 to date over 4 clinical trials, GP2 treatment was well tolerated and no serious adverse events were observed related to GP2 immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Acid Immunotherapy Surgery Cancer Treatment Breast Cancer Clinical Trial Treatment Of Breast Cancer Her2 Her2/Neu Cancer Center
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.44 |
| 52 Week Low | 7.58 |
| Average Volume | 41,422 |
| 200-Day Moving Average | 11.40 |
| 50-Day Moving Average | 15.64 |
| 20-Day Moving Average | 13.51 |
| 10-Day Moving Average | 13.88 |
| Average True Range | 1.05 |
| RSI (14) | 48.98 |
| ADX | 18.99 |
| +DI | 19.13 |
| -DI | 20.76 |
| Chandelier Exit (Long, 3 ATRs) | 11.64 |
| Chandelier Exit (Short, 3 ATRs) | 14.54 |
| Upper Bollinger Bands | 14.90 |
| Lower Bollinger Band | 12.11 |
| Percent B (%b) | 0.67 |
| BandWidth | 20.65 |
| MACD Line | -0.20 |
| MACD Signal Line | -0.39 |
| MACD Histogram | 0.1887 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 15.09 | ||||
| Resistance 3 (R3) | 15.15 | 14.83 | 14.91 | ||
| Resistance 2 (R2) | 14.83 | 14.55 | 14.81 | 14.84 | |
| Resistance 1 (R1) | 14.41 | 14.38 | 14.25 | 14.35 | 14.78 |
| Pivot Point | 14.09 | 14.09 | 14.02 | 14.07 | 14.09 |
| Support 1 (S1) | 13.67 | 13.81 | 13.51 | 13.61 | 13.18 |
| Support 2 (S2) | 13.35 | 13.64 | 13.33 | 13.12 | |
| Support 3 (S3) | 12.93 | 13.35 | 13.06 | ||
| Support 4 (S4) | 12.87 |
